Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Jiewei Lin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5056632597. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: none · 2025: 1 paper

Papers 12

  1. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  2. A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis. First author DOI 10.1007/s13402-023-00818-5↗
  3. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresi… First author DOI 10.1038/s41421-023-00592-6↗
  4. SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcino… Co-author DOI 10.1186/s13046-023-02890-z↗
  5. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  6. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  7. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. Co-author DOI 10.1186/s13045-022-01348-7↗
  8. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  9. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  10. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03985-1↗
  11. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Co-author DOI 10.1186/s13046-021-02097-0↗
  12. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? First author DOI 10.1016/j.pan.2019.03.005↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chenghong Peng · 7 shared papers, 2019–2023 · strength 0.92
  2. Baiyong Shen · 6 shared papers, 2019–2025 · strength 0.83
  3. Yizhi Cao · 5 shared papers, 2022–2025 · strength 0.73
  4. Hao Chen · 5 shared papers, 2019–2022 · strength 0.63
  5. Shuyu Zhai · 4 shared papers, 2021–2025 · strength 0.61
  6. Kai Qin · 4 shared papers, 2022–2025 · strength 0.59
  7. Xiaxing Deng · 4 shared papers, 2021–2023 · strength 0.56
  8. Da Fu · 3 shared papers, 2022–2023 · strength 0.51
  9. Lingxi Jiang · 4 shared papers, 2021–2022 · strength 0.51
  10. Siyi Zou · 3 shared papers, 2021–2025 · strength 0.46
  11. Jiancheng Wang · 3 shared papers, 2022–2023 · strength 0.44
  12. Zengyu Feng · 3 shared papers, 2022–2023 · strength 0.41
  13. Lijie Han · 3 shared papers, 2022–2023 · strength 0.41
  14. Kexian Li · 3 shared papers, 2022–2023 · strength 0.41
  15. Yongsheng Jiang · 3 shared papers, 2022–2023 · strength 0.41
  16. Baiyong Shen · 2 shared papers, 2022–2023 · strength 0.36
  17. Chenlei Wen · 2 shared papers, 2022–2025 · strength 0.33
  18. Pengyi Liu · 2 shared papers, 2023–2025 · strength 0.33
  19. Jiancheng Wang · 2 shared papers, 2022–2025 · strength 0.31
  20. Xinjing Wang · 2 shared papers, 2022 · strength 0.31
  21. Hao Chen · 2 shared papers, 2021–2023 · strength 0.28
  22. Jiaxin Luo · 2 shared papers, 2022–2023 · strength 0.28
  23. Xiaxing Deng · 2 shared papers, 2019–2022 · strength 0.25
  24. Yuchen Ji · 1 shared paper, 2023 · strength 0.20
  25. Weishen Wang · 1 shared paper, 2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.